Health Technology Review	
Technology Ref.:	**HTA19003**
Technology Name:	**Mammaprint: Genomic test indicated for Early Breast cancer patients**
Approvals by International Bodies:	**The Technology is Approved by US FDA.**
Company name:	**Advanced Care for the Management of Medical Facilities**
Agent in UAE:	**Dr Gilbert Karayakoupoglou**
Email:	gilbert.k@advanced-care.ae

Short Description of the Technology:	MammaPrint is a genomic test indicated for Early Breast cancer patients. The test analyzes 70 key genes and accurately determines which patients are at low risk of breast cancer recurrence and can therefore safely choose not to undergo chemotherapy. MammPrint have been widely used in luminal type breast cancer. Clinical application of this data pool is expected to play a major role in transforming the healthcare system with respect to the provision of more accurate, effective, and reliable disease management solutions. As per the study, the test helps physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods. Product is already in the market in UAE bit not Abu Dhabi. Regarding the Cost Effectiveness**,** UAE Breast Cancer Treatment Cost Overall Projected Savings per year is 15,920,670 AED**.** Also, 16% reduction in Chemotherapy cost per year.

Health Technology Assessment Team Recommendation:	**Approved**
Summary of Review:	

MammaPrint is a genomic test for Early stage invasive Breast cancer patients used in Hospitals that have oncology department (for Breast Cancer) such as Tawam, SKMC, SSMC, Burjel Medical City, Gulf Cancer Center, … etc.

Advantages	Disadvantages
As per the study the test helps physicians determine a patient's individual risk for metastasis	Invasive
Genomics, Cancer detection, personalized medicine	Expensive
Technology will provide benefit to the female breast cancer patient and the healthcare provider by decreasing cost of un-needed chemo therapy.	Might label patients which need chemo therapy as (no eligible). But this harm is of low value since: 1) Modality is FDA approved; 2) high level of evidence since the modality was and is being tested in randomized clinical trials
Cost effective	

We recommend an **approval of using this technology** with the following conditions:

1. The approval on using the product in tumor centers only and on applicable patients only.
2. Establishing a proper quality monitoring process and reporting of any adverse events or unwarranted consequences including safety issues of laboratory employees
3. Provision of regular updates and reports about the product to DOH upon request.
4. Any other documents or information requested regarding the product.

Moreover, DOH has the right to stop the product at any stage if deemed necessary, initial Conditions and any subsequent conditions must be satisfied before obtaining final approval. Failure to do so will reflect in provoking the approval.